伏诺拉生与艾司奥美拉唑治疗重度反流性食管炎的临床疗效

doi:10.3877/cma.j.issn.2095-8765.2024.01.002

目的

对比伏诺拉生与艾司奥美拉唑治疗重度反流性食管炎的临床疗效。

方法

选择2020年12月至2021年12月在新疆维吾尔自治区人民医院消化科明确诊断为重度反流性食管炎120例患者的临床资料，随机分为2组，每组60例，分别采用伏诺拉生、艾司奥美拉唑治疗，并在治疗4及8周行胃食管反流病量表(GERD-Q)评分评价临床症状及有效率，治疗8周后复查胃镜，评估黏膜愈合情况。

结果

伏诺拉生组4、8周临床症状改善的总有效率分别为66.67%、90.00%，艾司奥美拉唑组分别为63.33%，86.67%，2组差异无统计学意义(P>0.05)；治疗8周后，伏诺拉生组、艾司奥美拉唑组内镜下黏膜愈合总有效率分别为90.00%、88.33%，差异无统计学意义(P>0.05)。

结论

伏诺拉生、艾司奥美拉唑均可以有效改善重度反流性食管炎临床症状和促进黏膜愈合。

关键词: 重度反流性食管炎, 伏诺拉生, 艾司奥美拉唑, 症状, 内镜

Objective

To compare the clinical efficacy of vonoprazol and esomeprazole in the treatment of severe reflux esophagitis.

Methods

120 patients who were diagnosed severe reflux esophagitis in the gastroenterology department of the People's Hospital of Xinjiang Uygur Autonomous Region from December 2020 to December 2021.Randomly divided into 2 groups, 60 cases in each group, were treated with vonoprazol and esomeprazole respectively, the gastroesophageal reflux disease scale (GERD-Q) score used to evaluate clinical symptoms and effective rate after 4 weeks and 8 weeks of treatment,gastroscopy was re-examined to evaluate mucosal healing after 8 weeks treatment.

Results

The total effective rates of 4-week and 8-week clinical symptom improvement in vonoprazol group were 66.67% and 90.00%, respectively; the 4-week and 8-week clinical symptom improvement rates of esomeprazole group were 63.33%, respectively. 86.67%, and there was no significant difference in the improvement of clinical symptoms between the two groups after treatment (P>0.05). After 8 weeks of treatment, the total effective rates of endoscopic mucosal healing in the vonoprazol group and the esomeprazole group were 90.00% and 88.33%, respectively, and there was no significant difference between the two groups (P>0.05).

Conclusion

Both vonoprazol and esomeprazole can effectively improve the clinical symptoms of severe reflux esophagitis and promote mucosal healing.

Key words: Severe reflux esophagitis, Vonoprazol, Esomeprazole, Symptoms, Endoscopy

表1 胃食管反流病问卷量表计分标准（分）

1周内症状发生的频率	0 d	1 d	2~3 d	4~7 d
烧心	0	1	2	3
反流	0	1	2	3
上腹部中央疼痛	3	2	1	0
恶心症状	3	2	1	0
因烧心或反流影响睡眠	0	1	2	3
额外自行服用药物来缓解烧心和（或）反流	0	1	2	3

表1 胃食管反流病问卷量表计分标准（分）

1周内症状发生的频率	0 d	1 d	2~3 d	4~7 d
烧心	0	1	2	3
反流	0	1	2	3
上腹部中央疼痛	3	2	1	0
恶心症状	3	2	1	0
因烧心或反流影响睡眠	0	1	2	3
额外自行服用药物来缓解烧心和（或）反流	0	1	2	3

表2 2组患者用药前基本情况比较

组别	例数	年龄（岁，）	性别（例）		LA分级（例）		食管裂孔疝（例）
组别	例数	年龄（岁，）	男性	女性	LA-C级	LA-D级	食管裂孔疝（例）
伏诺拉生组	60	55.41 ±13.52	38	22	42	18	27
艾司奥美拉唑组	60	56.23 ±14.73	44	16	45	15	26

表2 2组患者用药前基本情况比较

组别	例数	年龄（岁，）	性别（例）		LA分级（例）		食管裂孔疝（例）
组别	例数	年龄（岁，）	男性	女性	LA-C级	LA-D级	食管裂孔疝（例）
伏诺拉生组	60	55.41 ±13.52	38	22	42	18	27
艾司奥美拉唑组	60	56.23 ±14.73	44	16	45	15	26

表3 2组治疗 4、8 周后临床症状改善情况比较

组别	例数	显效（例）	有效（例）	无效（例）	总有效率（%）
伏诺拉生组	60
4周		29	11	20	66.67
8周		41	13	6	90.00
艾司奥美拉唑组	60
4周		27	11	22	63.33
8周		38	14	8	86.67

表3 2组治疗 4、8 周后临床症状改善情况比较

组别	例数	显效（例）	有效（例）	无效（例）	总有效率（%）
伏诺拉生组	60
4周		29	11	20	66.67
8周		41	13	6	90.00
艾司奥美拉唑组	60
4周		27	11	22	63.33
8周		38	14	8	86.67

表4 2组治疗8 周后内镜下黏膜愈合情况比较

组别	例数	显效（例）	有效（例）	无效（例）	总有效率（%）
伏诺拉生组	60	42	12	6	90.00
艾司奥美拉唑组	60	41	12	7	88.33

表4 2组治疗8 周后内镜下黏膜愈合情况比较

组别	例数	显效（例）	有效（例）	无效（例）	总有效率（%）
伏诺拉生组	60	42	12	6	90.00
艾司奥美拉唑组	60	41	12	7	88.33

1	El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review[J]. Gut, 2014, 63(6): 871-880.
2	Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis[J]. Aliment Pharmacol Ther, 2001, 15(2): 227-231.
3	Gralnek IM, Dulai GS, Fennerty MB, et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials[J]. Clin Gastroenterol Hepatol, 2006, 4(12): 1452-1458.
4	Miner P, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study[J]. Am J Gastroenterol, 2004, 98(12): 2616-2620.
5	Wilder-Smith C, Lind T, Lundin C, et al. Acid control with esomeprazole and lansoprazole: a comparative dose-response study[J].Scand J Gastroenterol, 2007, 42(2): 157-164.
6	中华医学会消化病学分会. 2020年中国胃食管反流病专家共识[J].中华消化杂志, 2010, 40(10): 649-663.
7	李兆申, 王雯, 许国铭, 等.反流性食管炎1827例临床分析[J].中华内科杂志, 2001, 40(1):9-12.
8	Shaheen NJ, Weinberg DS, Denberg TD, et al. Upper endoscopy for gastroesophageal reflux disease:best practice advice from the clinical guidelines committee of the American College of Physicians[J]. Ann Intern Med, 2012, 157(11): 808-816．
9	Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population[J]. J Gastroenterol, 2009, 44(6): 518-534.
10	Richter JE. How to manage refractory GERD[J]. Nat Clin Pract Gastroentero Hepatol, 2007, 4(12): 658-664．
11	Dent J, Vakil N, Jones R, et al.Accuracy of the diagnosis of GERD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study[J]. Gut, 2010, 59(6): 714-721.
12	Bardhan KD, Hawkey CJ, Long RG, et al. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole clinical research group[J]. Aliment Pharmacol Ther, 1995, 9(2): 145-151.
13	Castell DO, Richter JE, Robinson M, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group[J]. Am J Gastroenterol, 1996, 91(9): 1749-1757.
14	Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis[J]. Aliment Pharmacol Ther, 2001, 15(2): 227-231.
15	Gralnek IM, Dulai GS, Fennerty MB, et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials[J]. Clin Gastroenterol Hepatol, 2006, 4(12): 1452-1458.
16	Miner P, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study[J]. Am J Gastroenterol, 2004, 98(12): 2616-2620.
17	Wilder-Smith C, Lind T, Lundin C, et al. Acid control with esomeprazole and lansoprazole: a comparative dose-response study[J].Scand J Gastroenterol, 2007, 42(2): 157-164.
18	Zheng RN. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis[J]. World J Gastroenterol, 2009, 15(8): 990-995.
19	Umegaki E, Iwakiri K, Hiramatsu N, et al. Tu1052 a phase 3, randomized, double-blind, multicenter study to evaluate the efficacy and safety of TAK-438 (10 mg or 20 mg once-daily) compared to Lansoprazole (15 mg Once-Daily) in a 24-week maintenance treatment for healed erosive esophagitis[J]. Gastroenterology, 2014, 146(5): 738-741.
20	Malfertheiner P, Lind T, Willich S, et al.Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study[J].Gut, 2005, 54(6): 746-751.
21	Lichtenstein DR, Cash BD, Davila R, et al. Role of endoscopy in the management of GERD[J]. Gastrointest Endosc, 2007, 66(2): 219-224.
22	Higuchi K, Joh T, Nakada K, et al. Is proton pump inhibitor therapy for reflux esophagitis sufficient?: a large real-world survey of Japanese patients[J]. Intern Med, 2013, 52(13): 1447-1454.
23	Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects-a randomised open-label cross-over study[J]. Aliment Pharmacol Ther, 2015, 42(6): 719-730.
24	Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects[J]. Aliment Pharmacol Ther, 2015, 41(7): 636–648.
25	Oshima T, Arai E, Taki M, et al. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis[J]. Aliment Pharmacol Ther, 2019, 49(2): 140-146.
26	Kinoshita Y, Sakurai Y, Shiino M, et al. Evaluation of the efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a phase Ⅲ, randomized, double-blind, placebo-controlled, multicenter study[J]. Curr Ther Res Clin Exp, 2016,81-82:1-7.
27	Kinoshita Y, Sakurai Y, Takabayashi N, et al. Efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a randomized, placebo-controlled, phase 3 study[J]. Clin Transl Gastroenterol, 2019, 10(11), 1-9.
28	Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis[J]. Aliment Pharmacol Ther, 2016, 43(2): 240-251.
29	Hershcovici T, Fass R. Nonerosive reflux disease (NERD) -an update[J]. J Neurogastroenterol Motil, 2010, 16(1): 8-21.
30	Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects[J]. Aliment Pharmacol Ther, 2015, 41(7): 636-648.
31	Hunt RH, Scarpignato C. Potassium-competitive acid blockers (P-CABs): are they finally ready for prime time in acid-related disease?[J]. Clin Transl Gastroenterol, 2015, 6(10): e119.
32	Hiramatsu N, Kudou K, Umegaki, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis[J].Aliment Pharmacol Ther, 2015, 42(6): 685-695.
33	Xiao Y, Zhang S, Dai N, et al. Phase Ⅲ, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis[J]. Gut, 2019, 69(2): 318-365.
34	Cremonini F, Ziogas DC, Chang HY, et al. Meta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease[J]. Aliment Pharmacol Ther, 2010, 32(1): 29-42.
35	Lee KJ, Son BK, Kim GH, et al. Randomised phase 3 trial: tegoprazan, a novel potassium-ompetitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis[J]. Aliment Pharmacol Ther, 2019, 49(7): 864-872.
36	Iwakiri K, Fujiwara Y, Manabe N, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021[J]. J Gastroenterol, 2022, 57(4): 267-285.
37	Olbe L, Lundell L. Medical treatment of reflflux esophagitis[J]. Hepatogastroenterology, 1992, 39(4): 322-324.

[1]	兰华, 高丽莎, 申明, 张铭光. 内镜黏膜下剥离术后溃疡出血的研究进展[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 467-469.
[2]	宋红霞, 吴玩呈. 内镜下甲状腺手术切口入路发展的研究进展[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 470-472.
[3]	张立一, 徐春晓, 单玉玺. sEST联合不同扩张时间EPBD治疗胆总管结石的随机临床试验[J]. 中华普外科手术学杂志(电子版), 2024, 18(03): 295-298.
[4]	刘军, 周代琴, 徐雪梅, 于仕杰. ERCP+EST+ENBD取石术对胆总管结石的疗效及安全性研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(03): 299-302.
[5]	莫淇舟, 柳建军, 叶木石, 黄兴端, 李健维, 李思宁, 黄健, 苏劲. 二期原通道经皮肾镜联合输尿管软镜治疗经皮肾镜术后残石[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(04): 380-385.
[6]	潘兴赫, 董翔, 杨海洋, 张雪斌, 甘卫东. 超选择性前列腺动脉栓塞治疗伴急性尿潴留的高危高龄前列腺增生[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(03): 237-242.
[7]	胡志伟, 吴继敏, 汪忠镐, 张美光. 胃食管反流病食管外症状抗反流手术适应证及术前评估[J]. 中华疝和腹壁外科杂志(电子版), 2024, 18(03): 241-246.
[8]	王冬澳, 林超, 鄂长勇. 胰腺术后出血原因及诊治策略[J]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 472-480.
[9]	杨渝, 吕云福, 郑进方. 内镜下Oddi括约肌切开取石术后对胆囊功能影响的研究进展[J]. 中华肝脏外科手术学电子杂志, 2024, 13(02): 235-238.
[10]	胡力, 魏士龙, 刚振博, 谢春成. 全内镜下三叉神经微血管减压术治疗三叉神经痛[J]. 中华脑科疾病与康复杂志(电子版), 2024, 14(03): 190-192.
[11]	陈雪飞, 卜雄建, 张春良. 神经内镜下经鼻蝶窦扩大鞍底入路颅咽管瘤切除术的疗效分析[J]. 中华脑科疾病与康复杂志(电子版), 2024, 14(03): 160-165.
[12]	刘燚隆, 党荣广, 艾蓉, 张凯. 肝硬化合并静脉曲张出血患者内镜治疗后再出血风险的模型建立与验证[J]. 中华消化病与影像杂志(电子版), 2024, 14(04): 336-342.
[13]	任爽, 刘懿颖, 李洋. 瑞巴派特联合艾司奥美拉唑治疗糜烂性胃炎的临床疗效[J]. 中华消化病与影像杂志(电子版), 2024, 14(03): 249-252.
[14]	陈磊, 高苏俊, 王璐, 倪修凡, 史茜菁, 朱振. 糖皮质激素序贯疗法预防环周食管浅表肿瘤内镜黏膜下剥离术后狭窄的研究[J]. 中华临床医师杂志(电子版), 2024, 18(02): 159-165.
[15]	王永彬, 贾彦迅, 尹轶广. 神经导航结合3D重建技术引导神经内镜血肿清除术对高血压脑出血患者的影响[J]. 中华脑血管病杂志(电子版), 2024, 18(02): 153-156.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Clinical observation of Vonoprazan versus esomeprazole in the treatment of severe reflux esophagitis

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Clinical observation of Vonoprazan versus esomeprazole in the treatment of severe reflux esophagitis